SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

Core Insights - SAb Biotherapeutics, Inc. is advancing its lead program, SAB-142, aimed at treating type 1 diabetes (T1D) and other autoimmune diseases, with significant data to be presented at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD) [1][2] Presentation Details - Four oral presentations and two poster presentations have been accepted for the ISPAD conference, showcasing the progress of SAB-142 in delaying T1D progression in new onset Stage 3 patients [1] - Key presentations include topics on specimen quality, binding specificities of SAB-142, immunomodulation without sustained lymphodepletion, and the mechanism of action of SAB-142 [3][4] SAB-142 Overview - SAB-142 is a fully human anti-thymocyte globulin (hATG) designed to modify the disease course of autoimmune T1D, targeting immune cells that destroy pancreatic beta cells [5][6] - The drug has shown a favorable safety profile in Phase 1 trials, not causing serum sickness or anti-drug antibodies at target doses [4][5] Company Background - SAB BIO focuses on developing multi-specific, high-potency human immunoglobulin G (hIgG) to treat immune and autoimmune disorders, with a proprietary platform for generating novel therapeutic candidates [6]